STVNHealthcare · Medical Instruments & SuppliesThe 13 Wall Street analysts covering Stevanato Group SpA hold a median 12-month price target of $25 — +27.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 26 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Stevanato Group SpA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (81): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (38): The shares have been drifting down relative to others.
Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on STVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +27.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Maintains | Neutral | $28 → $23 |
| 16 June 2026 | TD Cowen | Initiates | Buy | — |
| 2 June 2026 | Wolfe Research | Assumes | Outperform | $21 |
| 6 Mar 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 5 Mar 2026 | Citigroup | Maintains | Buy | — |
| 5 Mar 2026 | Keybanc | Maintains | Overweight | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Mar 2025 | UBS | Maintains | Neutral | — |
| 13 Dec 2024 | B of A Securities | Maintains | Buy | — |
| 13 Dec 2024 | Wolfe Research | Initiates | Outperform | — |
| 3 Dec 2024 | Morgan Stanley | Assumes | Equal-Weight | $24 → $23 |
| 7 Aug 2024 | Citigroup | Maintains | Buy | — |
| 15 July 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 22 Apr 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 25 Mar 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 1 Nov 2023 | Jefferies | Downgrade | Hold | — |
| 1 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 26 Sept 2023 | Stephens & Co. | Initiates | Overweight | — |
| 19 Sept 2023 | CJS Securities | Initiates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
STVN appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Stevanato Group SpA returned −24.1% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 27% of US stocks
Cheaper than 30% of US stocks
Cheaper than 16% of US stocks
Higher than 47% of US stocks
Higher than 19% of US stocks
Higher than 32% of US stocks
Higher than 75% of US stocks
Higher than 71% of US stocks
Higher than 61% of US stocks
Higher than 79% of US stocks
Higher than 73% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Stevanato Group SpA has a market value of $5.3B and an enterprise value of $6.4B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 7.8% year on year.
Net income over the same four quarters: $134.6M, a 11.0% net margin.
Diluted earnings per share, trailing twelve months: $0.48.
Free cash flow in the twelve months to 30 June 2026: −$30.7M.
Trailing P/E: 34.2×; forward P/E: 23.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.27%, paying out 11% of earnings.
Stevanato Group SpA employs 6,010 people — $204K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Stevanato Group SpA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, compared with -9.39% for the Russell 2000 Growth Index. Stevanato Group was listed among the composite’s top five leaders.
Why it matters — The report identifies Stevanato Group as one of the portfolio’s top-performing holdings during the quarter, though it provides no company-specific performance figures.
Stevanato Group announced a collaboration with Aptar Pharma to provide system-level data that supports earlier evaluation of pre-filled syringe configurations. The collaboration focuses on sensitive biologics and other injectable therapies.
Why it matters — The agreement highlights a collaboration aimed at helping biotech and pharmaceutical companies assess pre-filled syringe systems earlier in development.
Riverwater Partners’ Sustainable Value Strategy lagged the Russell 2500 Value Index in the third quarter of 2026. Stevanato Group was listed among the strategy’s top contributors.
Why it matters — The update identifies STVN as one of the portfolio’s top contributors during the quarter.
Stevanato Group announced that it will report third-quarter 2026 financial results on November 3, 2026, at 6:30 a.m. EDT. The company will host a conference call and webcast at 8:30 a.m. EDT that day.
Why it matters — STVN watchers can note the scheduled date and times for the company’s results announcement and investor call.
Stevanato Group S.p.A. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.
Why it matters — A transcript of Stevanato's presentation gives investors and watchers direct insight into the company's messaging and priorities shared with the investment community.
The 13 Wall Street analysts covering Stevanato Group SpA have a median 12-month price target of $25, with estimates ranging from $21 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Stevanato Group SpA, 9 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stevanato Group SpA 67 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Stevanato Group SpA ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (81 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +27.3% from the last close, and Ticker Nerd's factor model ranks Stevanato Group SpA 67 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Stevanato Group SpA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $32 over the next 12 months.
Stevanato Group SpA returned -24.1% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries.
The most recent item we track (Seeking Alpha, 27 Oct 2026): "Conestoga Small Cap Composite Q3 2026 Portfolio Activity". The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, compared with -9.39% for the Russell 2000 Growth Index. Stevanato Group was listed among the composite’s top five leaders.
Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries. The company focuses on drug containment, drug delivery, and diagnostic solutions, supplying products and services used across development, clinical, and commercial stages of the drug life cycle. Its portfolio includes containment systems such as vials, cartridges, syringes, and ampoules, alongside drug delivery devices, diagnostic consumables, analytical services, and medical devices. Stevanato Group also offers engineering capabilities through visual inspection, assembling, packaging, and glass-forming machinery, supporting manufacturing and packaging operations for biopharma customers. Headquartered in Piombino Dese, Italy, the company serves a global customer base across multiple healthcare and diagnostic markets.
CEO Mr. Franco Stevanato · 6,010 employees · Italy · https://www.stevanatogroup.com
